甲状腺激素受体β信号是前列腺癌生长的可向驱动因素
Aleksandra Fesiuk1,2, Daniel Pölöske1,3, Elvin D de Araujo4,5
1Department of Pathology, Medical University of Vienna, Vienna, Austria.
Molecular cancer
|October 15, 2025
概括
甲状腺激素受体β (TRβ) 驱动前列腺癌 (PCa) 的进展. 一种TRβ抗剂NH-3有效抑制PCa的生长和雄激素受体信号传递,显示出对抗割的PCa治疗的前景.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 甲状腺激素 (TH) 信号影响组织平衡和新陈代谢.
- 最近的研究表明THs与前列腺癌 (PCa) 的发展和进展有关.
- μ-晶 (CRYM) 被确定为参与PCa和雄激素受体 (AR) 信号交叉的T3拾取蛋白.
研究的目的:
- 调查甲状腺激素受体β (TRβ) 的作用,主要的TH信号传递因子,在PCa.
- 在PCa模型中评估TRβ选择性对手NH-3的治疗潜力.
主要方法:
- 使用PCa细胞系进行体外增殖试验.
- 在使用PCa异种移植模型的体内研究.
- 对AR和AR目标基因调节的机制研究.
- 对恩扎鲁胺的比较疗效分析.
- 对TRβ表达和突变的人类PCa数据集的分析.
主要成果:
- 与NH-3相对抗的TRβ抑制了PCa细胞增殖,并在体内减少了瘤大小.
- NH-3在耐化PCa (CRPC) 模型 (22Rv1细胞系) 中显示出显著的疗效.
- NH-3降低调节的AR及其目标基因,包括Nkx3.1和KLK3 (PSA).
- NH-3 显示出优于恩扎胺的疗效,在结合时具有协同效应.
- 增加的TRβ表达和TH通路突变与人类数据中的PCa发作相关.
结论:
- TRβ作为PCa瘤发生的关键调解剂.
- NH-3是PCa的强效治疗剂,特别有效地准CRPC中的AR信号.
- TRβ对抗是一种有前途的前列腺癌治疗策略.
相关概念视频
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
01:26Receptor Tyrosine Kinases
18.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.0K
01:16TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K